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(N  2379). Treatment completion is defined as receiving
at least 180 days of therapy at a minimum therapeutic
dose defined by the AHCPR guidelines. Patients were in-
cluded if they had a new ICD-9 diagnosis code for depres-
sion and were newly initiated on antidepressant therapy.
Patients were excluded if they were less than 18 years old,
had a diagnosis indicating schizophrenia or bipolar de-
pression, did not have at least 9 months of follow-up data
available, or were ineligible for coverage by the plan.
RESULTS: Total drug costs were higher in patients who
completed therapy ($704 versus $311; P  0.001); how-
ever overall healthcare costs were similar ($2672 versus
$2623, P  0.84). After controlling for confounding fac-
tors, there was a significant relationship between overall
cost and the specific antidepressant selected. Total costs
were similar for patients who switched or augmented
with a second antidepressant.
CONCLUSION: Patients with a diagnosis of depression
who complete therapy have similar overall healthcare
costs compared to those who do not. The initial antide-
pressant selected significantly contributes to overall costs.
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PATTERNS OF ANTIDEPRESSANT USE
Egan T, Baran R, McGhan W
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Antidepressants are a rapidly growing class of drugs used
to treat depression. The newer agents have been demon-
strated to improve patient outcomes and lower overall
health cost. Despite these benefits, the cost of the newer
antidepressants may be significant and may be influenced
by patterns of use. This study was undertaken to examine
three potential cost drivers associated with antidepres-
sants: persistence rate; switch rate; and concurrent use of
adjunctive antianxiety/sedative/hypnotic therapy.
OBJECTIVES: Examine the rates of persistence, switch-
ing, and concurrent use of adjunctive antianxiety/seda-
tive/hypnotic agents associated with the newer antide-
pressants and determine if there is a difference between
agents. Our objective was to determine if these differ-
ences in pattern of use add “cost” to treatment. Antide-
pressants studied included fluoxetine, paroxetine, sertra-
line, and venlafaxine.
METHODS: We performed a retrospective analysis of
medical and pharmaceutical claims data for 2,000,000
commercial HMO members for a 2-year period beginning
July 1996. Inclusion criteria for the study were: 1) diagno-
sis of depression; and 2) no antidepressant use or medical
activity related to depression for 3 months prior to admis-
sion to the study. The data were stratified into two groups
for review: non-capitated and capitated plans. Statistical
analysis was performed comparing each group.
RESULTS: There is a statistically significant difference
between some agents in the rates of switching and the use
of adjunctive medications. As switching increased, total
medical cost increased. Medical cost increased to $120
from $104 per depressed member per month at switching
rates of 29.5% and 15.3%, respectively. The variation in
the use and cost of adjunctive medications was also sta-
tistically significant between some agents. The cost ranged
from $23.71 to $2.74 for adjunctive medications per de-
pressed member per month.
CONCLUSION: When determining which antidepres-
sant drug to use, it is prudent to consider additional costs
associated with switching and adjunctive medication.
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Depression is a common, disabling and expensive psychi-
atric disorder. Management of depression has become a
heavy financial burden on both patients and society.
Pharmacotherapy can reduce the cost, but the question is
which drugs are most cost-beneficial.
OBJECTIVE: The purpose of this study is to investigate
and compare the costs and benefits of different antide-
pressants in the first year management of major depres-
sive disorder, from the perspective of a managed care
third-party payer.
METHODS: A decision tree was used to model the clini-
cal management of major depressive disorder (MDD).
Imipramine and paroxetine were chosen as examples of
two main classes of antidepressants, namely, the tricyclic
antidepressants (TCAs) and selective serotonin reuptake
inhibitors (SSRIs). A cost-benefit analysis was conducted.
The cost is the cost of the antidepressant drug treatment.
The benefit is defined as the average cost of avoided
dropout. The net benefit is the difference between the de-
fined benefit and the cost of each drug treatment.
RESULTS: Within the first year time period, the cost
of using imipramine was $81.39 and the benefit was
$169.25. For paroxetine, the cost was $261.33 and the
benefit was $201.81. The net benefit of imipramine was
$87.86 and for paroxetine, $59.52.
CONCLUSION: Based on the assumptions and parame-
ters included in this model, imipramine was found to be a
preferred choice of antidepressant in the management of
MDD during the first year compared with paroxetine.
Sensitivity analysis shows that the results are robust to
the average whole sale prices of imipramine and paroxet-
ine as well as the type of depression (“dysthymic-neu-
rotic” or “reactive”).
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OBJECTIVE: This study was designed to: 1) identify in-
dividuals with and without a claims diagnosis for depres-
sion who received new prescriptions for SSRI antidepres-
sants, and 2) describe SSRI usage patterns in those with
depression.
METHODS: This was a retrospective database claims
analysis. Medical and pharmacy claims records of pa-
tients 18–64 years from 13 United Health–affiliated
health plans were examined from 1/1/93 to 12/31/97. Pa-
tients had a 6-month SSRI-free period before the index
SSRI prescription; their claims were examined in the 6
months after their index prescription. They were identi-
fied as having an ICD-9 claims diagnosis for depression
or not. Results were adjusted using logistic regression.
RESULTS: Of 46,139 patients, 22,693 (49.1%) had a
depression diagnosis, 6515 (14.1%) for major depres-
sion. A lower proportion of patients with major depres-
sion diagnoses (18.5%) achieved stable SSRI therapy
(150 days) than did those with all depression diagnoses
(21%). However, a higher proportion of patients with
major depression diagnoses had their therapy switched,
augmented or titrated (34.8% versus 26.8%). Paroxetine
users (OR  0.53; 95% CI 0.44–0.64) and sertraline us-
ers (OR  0.59; 95% CI 0.48–0.73) were less likely to
achieve stable therapy relative to fluoxetine users. They
were also less likely to have their SSRI therapy aug-
mented (OR  0.84; 95% CI 0.73–0.96 and OR  0.84;
95% CI 0.72–0.99, respectively) but more likely to
switch therapy (OR  1.69; 95% CI 1.49–1.92 and
OR  1.32; 95% CI 1.14–1.52).
CONCLUSIONS: Approximately half the study subjects
had no diagnosis for depression. Patients with major de-
pression diagnoses received more alterations in therapy
than those with all depression diagnoses. Fluoxetine
treatment resulted in greater duration of therapy and less
switching.
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OBJECTIVE: To compare continuation rates of fluoxe-
tine and sertraline for treatment of depression in poor,
young women, a particularly high-risk subgroup.
METHODS: A cohort was identified using Ohio Medi-
caid claims data for 7/1/91 to 6/30/96. Patients were con-
tinuously enrolled 1 year prior until 1 year following in-
dex Rx. Included were females aged 25–44, diagnosis of
depression 30 days prior to index Rx. Patients were ex-
cluded if they had other mood disorders, were disabled,
were prescribed any antidepressant in the last year, or in-
dex Rx was prescribed by a mental health specialist. Pre-
scriptions were for 	30 days, without co-pays. Age, race-
adjusted multivariate regression models (ordinary, logistic)
were fit, stratified by depression type (single episode, re-
current). Outcome variables were: 1) short-term success,
defined as filling three consecutive Rxs for the same drug,
with the first two Rxs totaling 
30 days at usual starting
levels (20 mg fluoxetine, 50 mg sertraline), and 2) long-
term success, measured as the number of prescriptions
filled for the same drug in the following year, among
those classified as short-term success.
RESULTS: Sample size was 333: 182 fluoxetine, 151 ser-
traline. Recurrent depression accounted for 44% of
cases. Drug choice was similar for both depression types.
Assuming 30-day Rxs, average daily dose was compara-
ble to that found in surveillance studies. Multivariate
models produced conflicting results for the two depres-
sion types. In single depression, sertraline had fewer short-
term successes (OR  0.496; 95% CI 0.272–0.901]), with
no statistically significant difference in long-term success.
In recurrent depression, although there was no difference
in short-term success, sertraline users filled 2.6 additional
prescriptions in the coming year (p  0.02).
CONCLUSION: Fluoxetine had better short-term contin-
uation rates in single-episode depression, sertraline had
better long-term continuation in recurrent depression.
PNP9
ANTIDEPRESSANT IMPACT ON 
SOCIAL FUNCTIONING: REBOXETINE 
VERSUS FLUOXETINE
Venditti LN1, Arcelus A1, Birnbaum H1, Greenberg P1, Barr 
CE2, Rowland C2, Williamson T2
1Analysis Group/Economics, Cambridge, MA, USA; 
2Pharmacia & Upjohn, Kalamazoo, MI, USA
Depression has an impact on social functioning which may
lead to a decrease in work productivity by affected individ-
uals. Selective serotonin reuptake inhibitors (SSRIs) such
as fluoxetine are commonly used to treat patients with this
disorder. However, reboxetine, one of the first in the new
class of non-tricyclic selective noradrenaline reuptake in-
hibitors (NRIs), may lead to improved social functioning
due to noradrenaline’s effect on motivation.
OBJECTIVE: The purpose of this analysis was to evalu-
ate the effect of reboxetine relative to fluoxetine in regard
to social functioning, as measured by a validated 21-item
self rating scale, the Social Adaptation Self Evaluation
Scale (SASS).
METHODS: A model using longitudinal patient data
from two 8-week clinical trials was developed using a
mixed-model analysis of variance approach. Using data
from 282 depressed patients, this model depicts the per-
centage change from baseline SASS score as a function of
both time-invariant and time-varying covariates, con-
founding variables, and covariate interactions. Time-
varying covariates include the percentage change from
baseline Hamilton Depression scale score (HAM-D), and
